The latest documents for national drug collection flowed out.

recently, a guide on the use of national selection varieties, requiring the strengthening of the use of medical institutions in the assessment of selected varietiesIt is reported that the main purpose of the document is to further enhance the enthusiasm of medical institutions and medical personnel to participate in the reform, and comprehensively strengthen the use of selected productsin this regard, the relevant industry to SeiberLan said that the relevant departments to introduce policies to strengthen the use of the volume of procurement of selected products is not difficult to understand, after all, if the non-selected products can also be used, after the enthusiasm of enterprises to participate in the collection will be reducedthe guidance clearly, the collection of drugs to implement the health insurance fund budget management, that is, the total amount of the health insurance fund is expected to spend on all products under the generic namebalance retention fund calculation formula (reference)collection drug medical insurance fund budget , agreed purchase amount basis , the weighted average price of the general name drug before collection , the proportion of actual payment of the general name drug co-ordination area , the proportion of patients using the general name co-ordination area
according to the above formula, in addition to the right side of the same number in the collection of drug weighted average price, the actual payment ratio of the regional medical insurance funds, medical institutions can not be around the total amount of the total In short, the higher the amount and usage of the hospital, the more health care funds the hospital can getdocument also stipulates that if the number of selected varieties used by hospitals exceeds the reported amount, the excess does not count towards the amount of medical insurance expenditure for the collection of generic drugs, and still calculates the expenditure according to the agreed purchase amount, and will not reduce the health insurance balance fundsplus the previous policy provisions, hospital procurement of selected varieties exceeded the procurement of the part, the winning enterprises are still in accordance with the price of the winning supplyThese initiatives have reduced the worry of hospitals using selected productsThere is also a formula in theguidance on the balance measurement base - balance measurement base - collection of drug health insurance fund budget - (the purchase volume of selected products agreed to the amount of the winning price and the amount of non-selected products used) - the actual average reimbursement ratio of the regional health insurance fund , the proportion of patients insured in the general famous drug co-ordination area
according to this formula, in the collection of drug medical insurance funds budget and the proportion of local medical insurance reimbursement and the proportion of patients to obtain as much as possiblein this regard, Minsheng Pharmaceutical Product strategy director Zhang Tingjie told Seibrand, this document for the national collection of the winning products is a good, non-winning products are more difficult to sellShen Yong, chairman of Beijing ShengshiKanglai Chinese Medicine Marketing Planning Company, also pointed out that for alternative strong varieties, there is no doubt that a crisis, the impact of the relatively weaker products is relatively smallin the process of promoting the centralized procurement of drugs organized by the state organization, the relevant departments have repeatedly emphasized the purchase of the volume, the exchange of prices, to ensure the combination of recruitment and the use of the samefor example, the "Notice of the General Office of the State Council on the Issue of the Pilot Program for the Central Procurement and Use of Drugs of State Organizations" issued on January 17, 2019 makes it clear that public medical institutions in the pilot areas should be used as a priority to ensure the completion of contract usage within one year through the identification of centralized procurement varieties determined in different forms such as tenders, bargaining and negotiations at the same time, the notice requires the compaction of the responsibility of the medical institution to ensure the dosage - encourage the use of the selected drugs, the use of the winning drugs into the performance appraisal of medical institutions and medical personnel , driven by the policy, from the overall data, the first batch of national collection exceeded expectations completed - "2019 National Medical Security Development Statistics Bulletin" shows that by the end of 2019, "4 plus 7" drug centralized procurement pilot areas 25 selected drugs completed an average of 183 percent of the agreed procurement volume, the procurement of selected drugs accounted for 78 percent of the same generic drug procurement volume the current first batch of volume procurement smooth lying official, the second batch of volume procurement has been fully landed, in the first batch of volume procurement of the overall procurement volume almost doubled, the relevant departments again issued to ensure the use of selected drugs policy documents, worthy of attention in this regard, the former President of the Zhejiang Pharmaceutical Industry Association Guo Taihong said to Seibai Lan today, "In theory, is not allowed to buy the results of the hospital, otherwise to collect what?" Under the existing policy, hospitals report less, use more, get no benefits, to benefit, we need the Health Care Board to introduce a new policy." say that one of the aims of this policy document may be to further strengthen the use of selected breeds in hospitals related industry insiders also expressed his views on this issue - if all the collection varieties in the hospital procurement and use are completed very ideal, the relevant departments do not need to issue redundant documents, since the relevant documents have been issued, it is indicated that at least at present, some collection varieties in the hospital procurement and use is problematic according to the industry to Seiberlan revealed that there are individual collection varieties of the agreed procurement volume has not been completed, the main reason is - because of chronic disease medication, patient compliance is relatively strong, the brand effect of the original research products is better, resulting in the selection of products did not successfully achieve its replacement, some patients in the hospital do not give the original research drug, will directly choose the purchase of drugs, rather than accept the selection of generic drugs can be seen from the above situation, the purpose of this document may be to further ensure the use of selected varieties, in order to urge hospitals to complete the agreed procurement volume, especially for some of the varieties that have difficulty in completing further pointed out that, in addition to the original research products, the role of the replacement of the selected varieties is also related to the strength of the selected enterprises, if the promotion of the selected enterprises and other comprehensive strength is relatively strong, the process of playing the role of substitution will be relatively smooth according to the guidance, after determining the basis of the health insurance balance measurement base, according to the assessment results, the hospital can get up to 50% of the health insurance balance fund incentives , in addition, for hospitals, the guidance also set up ten assessment indicators, of which , the three major indicators are provinces (autonomous regions, municipalities directly under the Central Government) or the overall area can not be modified, respectively: 1, whether to complete the state organization on time of the centralized procurement of selected drugs agreed procurement volume; Dong Lei told Seberlan that for the pharmaceutical companies involved in the national collection, after the completion of price measurements, quotations, the most concern is the purchase volume and return in addition to the above three indicators, reasonable control of drug costs is also within the scope of assessment, including: fixed-point medical institutions drug cost growth rate, non-selected product procurement ratio, non-selected product procurement amount, similar efficacy of other generic name drug costs comprehensive ten assessment indicators can be seen, to ensure that the use of selected products and control hospital drug costs are closely related, and with the pressure of medical insurance funds to increase, hospital control fees will be strengthened, for non-selected drugs will also be increased drug costs control.